Last updated: August 21, 2026
Fluorometholone is a mature ophthalmic corticosteroid with limited molecule-level exclusivity and substantial generic competition. The commercial opportunity is concentrated in formulation performance, preservative reduction, patient tolerability, delivery devices, manufacturing efficiency, and differentiated ophthalmic presentations. The most attractive targets are preservative-free suspensions, low-residue formulations, improved redispersibility, ophthalmic ointments, and novel delivery systems that can support a 505(b)(2) strategy.
What products contain fluorometholone and how are they formulated?
Fluorometholone is marketed primarily as an ophthalmic suspension, with fluorometholone or fluorometholone acetate commonly supplied at 0.1%. A higher-strength 0.25% presentation has also been marketed. Ophthalmic ointment products have also existed.
| Product or product type |
Active ingredient |
Typical strength |
Dosage form |
Commercial formulation issue |
| FML ophthalmic suspension |
Fluorometholone |
0.1% |
Suspension |
Particle settling, shaking requirement, preservative exposure |
| FML Liquifilm |
Fluorometholone |
0.1% |
Suspension |
Multidose preservation and suspension uniformity |
| FML Forte |
Fluorometholone |
0.25% |
Suspension |
Higher steroid loading and dose uniformity |
| Flarex |
Fluorometholone acetate |
0.1% |
Suspension |
Acetate ester, particle control, preservative system |
| Generic fluorometholone products |
Fluorometholone or fluorometholone acetate |
Generally 0.1% |
Suspension or ointment |
Price competition and limited product differentiation |
| Ophthalmic ointment products |
Fluorometholone |
0.1% |
Ointment |
Blurred vision, patient acceptance, preservative and packaging choices |
The principal formulation challenge is that fluorometholone is delivered as a dispersed solid rather than a clear aqueous solution. The product must maintain dose uniformity after storage, transport, and repeated use. FDA labeling instructs patients to shake ophthalmic suspensions before use, reflecting the importance of sedimentation control and redispersion performance.[1-3]
What excipients are used in fluorometholone ophthalmic products?
Label-listed excipients vary by product, but common functional categories include:
| Excipient category |
Representative materials |
Primary function |
| Suspending and viscosity agents |
Polyvinyl alcohol, povidone |
Slow sedimentation and improve dose uniformity |
| Surfactants |
Polysorbate 80 |
Improve wetting and dispersion of drug particles |
| Tonicity agents |
Sodium chloride |
Adjust osmolarity toward ocular tolerability |
| Buffering agents |
Sodium phosphate salts |
Control pH and formulation stability |
| Chelating agents |
Edetate disodium |
Bind trace metals and support preservative performance |
| Preservatives |
Benzalkonium chloride |
Control microbial growth in multidose containers |
| Vehicle |
Purified water or water for injection |
Aqueous continuous phase |
| Ointment base |
Mineral oil and petrolatum-type materials |
Provide semisolid ocular delivery |
The formulation architecture is conventional. That limits barriers to generic substitution but creates room for incremental innovation in excipient selection, particle engineering, container closure, and administration convenience.
Which excipients offer the strongest commercial differentiation?
Preservative-free systems
Benzalkonium chloride is widely used in multidose ophthalmic products, but repeated exposure can damage the ocular surface, particularly in patients with dry eye, chronic inflammatory disease, glaucoma, or prolonged treatment requirements.[4] A preservative-free fluorometholone product could target:
- Postoperative patients requiring repeated topical steroid dosing
- Patients with ocular surface disease
- Patients receiving multiple preserved ophthalmic products
- Prescriber preference for preservative-free corticosteroids
- Institutional formularies with ocular-surface safety criteria
Commercial formats could include unit-dose vials, preservative-free multidose pumps, and sterile metered-dose dispensers. The main tradeoff is higher packaging cost, greater sterility-control burden, and reduced container convenience compared with conventional multidose bottles.
Improved suspension systems
Polyvinyl alcohol and povidone are established ophthalmic excipients that can improve wetting and suspendability. A differentiated system could use:
- Optimized viscosity without excessive blinking discomfort
- Narrow particle-size distribution
- Surface modification of fluorometholone particles
- Better redispersion after prolonged storage
- Reduced settling during normal patient handling
- More consistent dose delivery from the first through the last dose
A formulation that remains uniform after limited shaking could have practical value, but the product would need robust comparative testing. Key performance measures include sedimentation rate, redispersion time, delivered-dose uniformity, particle-size distribution, rheology, and chemical stability.
Low-viscosity or gel-forming vehicles
Viscosity enhancers can prolong ocular residence time but may cause blurred vision, transient discomfort, or poor patient acceptance. A gel-forming fluorometholone formulation could provide longer residence without the visual burden of an ointment.
Potential excipient platforms include:
- In situ gelling polymers
- Mucoadhesive polymers
- Thermoresponsive systems
- Ion-activated polysaccharides
- Low-concentration cellulose derivatives
These systems would create a stronger formulation and method-of-use patent position than a conventional aqueous suspension. They also introduce more demanding development work around preservative distribution, extractables and leachables, sterility, viscosity changes across temperature ranges, and dose delivery.
What formulation patents could protect a fluorometholone product?
The active ingredient itself is a mature small molecule. Commercial protection would therefore depend on secondary patents and regulatory exclusivity rather than composition-of-matter rights.
Potential patentable subject matter includes:
- Particle engineering. Specific particle-size distributions, crystal forms, surface treatments, or milling conditions.
- Suspension composition. Defined ratios of fluorometholone, polymer, surfactant, buffer, tonicity agent, and preservative.
- Preservative-free delivery. Unit-dose or multidose sterile packaging combined with a defined fluorometholone suspension.
- Ophthalmic gel systems. Polymer combinations that produce a targeted viscosity or gelation profile.
- Ointment formulations. Reduced-blur bases, improved drug uniformity, or enhanced drug release.
- Container-closure systems. Metered-dose pumps, low-retention droppers, and dose-counting packages.
- Manufacturing processes. Aseptic particle processing, sterilization-compatible manufacturing, or controlled homogenization.
- Therapeutic use. Narrowly defined postoperative, inflammatory, or ocular-surface indications supported by clinical data.
A patent estate based only on excipient substitutions is generally vulnerable if the change would be predictable to a formulation scientist. Stronger claims combine measurable performance characteristics with a defined composition and supporting clinical or stability data.
When does fluorometholone lose exclusivity?
Fluorometholone lost its original molecule-level exclusivity decades ago. The product is now a mature generic ophthalmic corticosteroid. FDA-approved versions have historically entered through abbreviated pathways, and generic competition is the primary market constraint.[5]
| Exclusivity category |
Fluorometholone position |
| New chemical entity exclusivity |
Expired |
| Composition-of-matter patent |
Expired or commercially irrelevant |
| Current product-level exclusivity |
No meaningful broad exclusivity identified |
| Biosimilar exclusivity |
Not applicable |
| Generic competition |
Established |
| Main protection opportunity |
Formulation, device, manufacturing, and use patents |
Exact patent expiration analysis must distinguish the original fluorometholone compound from later product-specific patents. For current commercial planning, the relevant conclusion is that an innovator cannot rely on the active ingredient to block generic entry.
What is the Orange Book status of fluorometholone?
Fluorometholone is an FDA-regulated small-molecule ophthalmic drug, not a biologic. Approved products and product-specific patents are tracked through FDA databases, including the Orange Book and Drugs@FDA.[5,6]
The commercial significance of the Orange Book position is limited:
- Generic applicants can generally pursue an ANDA for a pharmaceutically equivalent ophthalmic product.
- A generic applicant may use a Paragraph IV certification if it challenges a listed patent.
- A new formulation that changes the delivery system, clinical profile, or labeling may require a 505(b)(2) application rather than a standard ANDA.
- Formulation patents may delay or complicate entry only if they are listed, enforceable, and relevant to the proposed generic product.
A conventional fluorometholone suspension with the same active ingredient, strength, dosage form, route, and applicable labeling is structurally exposed to ANDA competition.
How do Paragraph IV challenges affect fluorometholone?
Paragraph IV risk is lower for the old core products than for recently launched ophthalmic formulations because the original products do not depend on active composition patents. The main litigation risk would arise from:
- A newly developed preservative-free product
- A device-specific formulation
- A novel nanosuspension
- A gel-forming formulation
- A product with newly granted method-of-use patents
- A 505(b)(2) product with listed formulation patents
A generic applicant challenging a later fluorometholone formulation could seek to establish that the asserted claims are invalid, not infringed, or not relevant to the proposed ANDA product. Conversely, the innovator could argue that the generic product falls within composition, particle-size, manufacturing, or device claims.
For conventional products, the more probable market outcome is price erosion through multiple ANDA entrants rather than extended patent litigation.
What regulatory pathway applies to a new fluorometholone formulation?
ANDA pathway
An ANDA is appropriate when the proposed product matches the reference product in the required pharmaceutical and labeling characteristics. For fluorometholone ophthalmic suspension, the developer would need to address:
- Active ingredient identity
- Strength and dosage form
- Sterility
- Particle-size distribution
- Redispersibility
- Delivered-dose uniformity
- pH and osmolality
- Viscosity
- Preservative effectiveness
- Container-closure integrity
- Stability
- Inactive ingredient safety
Ophthalmic suspensions create a more complex equivalence package than simple aqueous solutions because the dispersed phase can affect performance and ocular exposure.[7]
505(b)(2) pathway
A 505(b)(2) application could support:
- A preservative-free multidose product
- A long-residence gel
- A novel metered-dose delivery system
- A different strength or dosing regimen
- An ointment with a modified release profile
- A formulation that relies partly on published data or prior FDA findings
The 505(b)(2) route can create regulatory exclusivity and a more defensible commercial position, but it usually requires clinical or comparative data beyond a conventional ANDA.
What generic entry risks exist for fluorometholone?
Generic entry risk is high for standard fluorometholone suspensions and ointments. The principal sources of erosion are:
- Multiple approved ANDA products
- Therapeutic substitution within topical ophthalmic steroids
- Low switching costs for pharmacies and payers
- Limited prescriber attachment to a mature brand
- Commodity excipient systems
- Absence of meaningful active-ingredient exclusivity
Risk is lower for a differentiated product when the product has:
- Preservative-free packaging
- Demonstrated tolerability advantage
- Superior dose uniformity
- Reduced shaking requirement
- Longer ocular residence
- A proprietary delivery device
- Clinical evidence supporting a specific patient population
A conventional generic can launch rapidly after applicable patent and regulatory barriers are cleared. A 505(b)(2) product may support a higher price, but it must demonstrate a clinical or administration benefit that payers and prescribers recognize.
How does fluorometholone compare with competing ophthalmic steroids?
| Drug |
Typical commercial position |
Formulation and commercial comparison |
| Fluorometholone |
Lower-potency topical ophthalmic corticosteroid |
Mature, low-cost, suspension-focused market |
| Prednisolone acetate |
Widely used ophthalmic steroid |
Strong generic competition and established prescriber familiarity |
| Dexamethasone |
Ophthalmic steroid available in multiple combinations |
Broad clinical use and generic price pressure |
| Loteprednol etabonate |
“Soft steroid” positioned around ocular safety |
Greater branded differentiation and stronger formulation economics |
| Difluprednate |
Higher-potency ophthalmic steroid emulsion |
Premium positioning, higher potency, more active commercial differentiation |
Fluorometholone’s opportunity is not to compete primarily on potency. It is to compete on tolerability, convenience, preservative exposure, dosing consistency, and total treatment experience. Loteprednol is the closest commercial benchmark for a formulation-led premium strategy, although fluorometholone would need differentiated evidence to justify a higher price.[8]
Which licensing and partnership opportunities exist?
No broad, current licensing transaction is required to commercialize a conventional generic fluorometholone product. The more valuable partnership opportunities are platform-based:
- Licensing a preservative-free ophthalmic container
- Acquiring a sterile suspension manufacturing process
- Partnering with an ophthalmic polymer developer
- Licensing particle-engineering technology
- Contracting a manufacturer with validated aseptic suspension capacity
- Co-developing an ocular-surface safety study
- Partnering with a specialty ophthalmology company for 505(b)(2) commercialization
For a generic manufacturer, the economic case favors manufacturing and packaging partnerships. For a specialty pharmaceutical company, a formulation or device license is more defensible than a license covering fluorometholone alone.
How strong is the fluorometholone patent estate?
The core patent estate is weak because the active ingredient is old and genericized. A new product-specific estate could be moderate to strong if it combines:
- Narrow composition claims
- Defined particle characteristics
- Device claims
- Manufacturing claims
- Clinical data
- A regulatory exclusivity period
- A clear patient benefit
The weakest strategy is a patent that claims routine excipient substitutions without unexpected performance data. The strongest strategy links the excipient system to a measurable outcome, such as improved redispersion, reduced preservative exposure, enhanced residence time, or a validated reduction in dosing variability.
What is the commercial opportunity for fluorometholone excipients?
The best opportunities are specialty products rather than undifferentiated generic suspensions.
| Opportunity |
Development burden |
Pricing potential |
Patent potential |
| Standard generic suspension |
Low to moderate |
Low |
Low |
| Improved redispersibility suspension |
Moderate |
Moderate |
Moderate |
| Preservative-free unit-dose product |
Moderate |
Moderate |
Moderate |
| Preservative-free multidose pump |
High |
High |
High |
| In situ gel formulation |
High |
High |
High |
| Novel ophthalmic ointment |
Moderate |
Moderate |
Moderate |
| Sustained-release insert or depot |
Very high |
High |
High |
| Combination product |
High |
Moderate to high |
Moderate to high |
Revenue exposure for incumbent fluorometholone brands is likely concentrated in product-level pricing, pharmacy substitution, and ophthalmology channel access rather than exclusivity rents. Public company reporting generally does not isolate fluorometholone revenue from broader ophthalmology portfolios. The most defensible commercial forecast is therefore scenario-based: standard generic products face continuing price erosion, while differentiated preservative-free or device-enabled products can preserve margin through clinical and usability benefits.
Key Takeaways
- Fluorometholone is a mature small-molecule ophthalmic corticosteroid with high generic-entry exposure.
- The core active ingredient provides little current exclusivity value.
- Excipient strategy should focus on suspension stability, redispersibility, ocular-surface tolerability, and preservative reduction.
- Benzalkonium chloride replacement or elimination is the clearest patient-centered differentiation route.
- A standard formulation is generally suited to an ANDA strategy.
- A gel, novel multidose package, preservative-free system, or modified dosing profile may support a 505(b)(2) strategy.
- Stronger patents will combine composition, particle engineering, device, manufacturing, and performance claims.
- Biosimilar competition does not apply because fluorometholone is a small molecule.
- The commercial upside is greater for specialty formulations than for conventional generic suspensions.
- The principal competitive benchmarks are prednisolone acetate, dexamethasone, loteprednol etabonate, and difluprednate.
FAQs about fluorometholone formulation and market opportunities
Can fluorometholone be formulated as a clear ophthalmic solution?
A conventional fluorometholone product is generally supplied as a suspension because of the drug’s limited aqueous solubility. A clear solution would require a substantially different solubilization approach and would need extensive evaluation for ocular tolerability, stability, dose uniformity, and preservative compatibility.
Is preservative-free fluorometholone commercially attractive?
Yes. A preservative-free presentation could target patients with chronic ocular-surface sensitivity, postoperative treatment needs, or multiple preserved eye drops. Packaging cost and sterile manufacturing complexity are the primary commercial constraints.
Could fluorometholone support a sustained-release ophthalmic product?
Potentially. A sustained-release insert, depot, implant, or contact-lens delivery system could support stronger formulation and device patents. The development burden would be materially higher than for a topical suspension and would likely require clinical evidence supporting safety and duration of effect.
Which excipient is most important for fluorometholone suspension performance?
The answer depends on the target product profile. Suspending polymers such as polyvinyl alcohol or povidone influence sedimentation and redispersion, while surfactants such as polysorbate 80 can improve particle wetting. The commercial objective should be optimized system performance rather than substitution of one excipient in isolation.
Does fluorometholone have biosimilar risk?
No. Fluorometholone is a chemically synthesized small molecule. Competitive products enter through generic drug pathways, including ANDAs, rather than the biosimilar pathway.
References
- DailyMed. (n.d.). FML ophthalmic suspension: Fluorometholone ophthalmic suspension prescribing information. U.S. National Library of Medicine.
- DailyMed. (n.d.). FML Liquifilm ophthalmic suspension: Fluorometholone ophthalmic suspension prescribing information. U.S. National Library of Medicine.
- DailyMed. (n.d.). Flarex ophthalmic suspension: Fluorometholone acetate ophthalmic suspension prescribing information. U.S. National Library of Medicine.
- U.S. Food and Drug Administration. (2023). Ophthalmic drug products for topical administration: Guidance for industry.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research.
- U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs.
- U.S. Food and Drug Administration. (2013). Guidance for industry: ANDAs for certain highly purified synthetic peptide drug products that refer to listed drugs of recombinant origin.
- DailyMed. (n.d.). Loteprednol etabonate ophthalmic suspension prescribing information. U.S. National Library of Medicine.
